Changing the Course of Patient Outcomes in Non-Small-Cell Lung Cancer: Novel Therapeutic Approaches for Early-Stage Disease

Download All
In this comprehensive program for oncology professionals, learn how the experts are leveraging emerging data on immunotherapy-based approaches for neoadjuvant and adjuvant treatment of early-stage NSCLC, including concise text-based modules from multidisciplinary perspectives, an on-demand webcast capturing a live CCO community workshop, downloadable slidesets, and a clinical resource PDF to facilitate shared-decision making with your patients.
person default
Patrick Forde, MB BCh
Stefanie Houseknecht, PharmD, BCOP
person default
Jonathan Spicer, MD, PhD, FRCS

Microlearning Activities with Downloadable Slidesets

In this module, a medical oncologist shares his expert perspective on emerging immunotherapy strategies in the neoadjuvant and adjuvant settings for the treatment of resectable early-stage NSCLC.

person default Patrick Forde, MB BCh Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: August 26, 2021 Expired: August 25, 2022

Download this slideset to review key data on the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

person default Patrick Forde, MB BCh Released: August 26, 2021

In this module, a pharmacist shares her perspective on monitoring for and managing toxicities associated with emerging immunotherapy strategies in the neoadjuvant and adjuvant settings for the treatment of resectable early-stage NSCLC.

Stefanie Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: October 12, 2022

Download this slideset presenting a pharmacist perspective on key data and toxicity management strategies for optimal use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Stefanie Houseknecht, PharmD, BCOP Released: October 13, 2021

In this module, a surgeon shares his expert perspective on the use of neoadjuvant immune checkpoint inhibitor–based therapy in resectable early-stage NSCLC.

person default Jonathan Spicer, MD, PhD, FRCS Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: December 1, 2021 Expired: November 30, 2022

Download this slideset to review key data on the use of neoadjuvant immune checkpoint inhibitor–based therapy in resectable early-stage NSCLC from a surgeon’s perspective.

Released: December 1, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue